AliveDx, FDA

AliveDx kündigt US FDA 510-Antrag für MosaiQ AiPlex® Celiac Disease -Multiplex-Mikroarray an

Published on 08/07/2025 at 18:05 | prnewswire.co.uk

AliveDx Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom California United States of America Europe

View original content:https://www.prnewswire.com/news-releases/alivedx-kundigt-us-fda-510k-antrag-fur-mosaiq-aiplex-celiac-disease-cd-multiplex-mikroarray-an-302371801.html

en | boerse | 67973883 |